# Eisai Innovation

> Eisai Innovation is a VC fund in Cambridge backing Biotechnology and Biopharma. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 10
- Last investment: Apr 2026
- Lead investor: 30%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/eisai-innovation-inc
- Website: https://www.eisaiinnovation.com

Eisai Innovation is a VC fund in Cambridge focused on Biotechnology and Biopharma. Eisai Innovation, Inc. is a strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 30% |
| Biopharma | 2 | 20% |
| Life Science | 2 | 20% |
| Therapeutics | 1 | 10% |
| Food and Beverage | 1 | 10% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 30% |
| Pre-Seed | 1 | 10% |
| Series A | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 20% |
| China | 1 | 10% |
| Israel | 1 | 10% |
| Hong Kong | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Microtide Biotechnology | Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M | Series A | Apr 29, 2026 |  |
| Excalipoint Therapetics | Excalipoint Therapeutics is a Private limited company. | $27.7M | Seed | Mar 18, 2026 |  |
| Tacit Therapeutics | Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California. | $19M | Series A | Mar 09, 2026 |  |
| Sift Biosciences | Sift Biosciences is a biotechnology research company that offers cancer therapies. | $3.8M | Pre-Seed | Dec 19, 2025 |  |
| EGenesis | EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $191M | Series D | Sep 04, 2024 |  |
| Hyku | Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins. The Hyku platform identifies molecules that covalently bind non-cysteine amino acids to aid in the creation of innovative medicines that can address present issues with a variety of disease targets, such as selectivity, druggability, and resistance. | $56M | Seed | Sep 19, 2023 |  |
| Tacit Therapeutics | Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California. | $9.5M | Venture - Series Unknown | Jun 08, 2022 |  |
| SOLA Biosciences | Sola Bio develops a modular bioreactor called Sola that empowers people to grow cells. |  | Seed | Sep 09, 2021 |  |
| Altoida | Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR),and artificial intelligence (AI).Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt. |  | Venture - Series Unknown | Jul 06, 2021 |  |
| Voluntis | Voluntis is a healthcare software company specialized in Patient Relationship Management (PRM). Their mission is to enable healthcare organizations to deliver outstanding patient monitoring and support services through the use of advanced information and communication technologies.Voluntis was founded in 2001 by three entrepreneurs who believedthat innovative medical solutions built with advanced information technologies would improve medical real-life outcomes and thus increase healthcare system efficiency. This would transform patient lives, enhance medical practices and quality of care.Every day, Voluntis teams seek to invent secure, collaborative and patient-centric digital health solutions with a unique combination of web and mobile development excellence, medical and regulatory expertise and certified quality-oriented processes. With more than 600,000 patients managed and more than 50 programs deployed, their track record speaks for itself. |  | Post-IPO Equity | Apr 27, 2021 |  |

10 of 10 investments shown.

## Co-investors
- [Apricot Capital](https://shizune.co/investors/profile/apricot-capital-ceb8) — VC Fund, 2 deals together
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together
- [Centurium Capital](https://shizune.co/investors/profile/centurium-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Eisai Innovation invest in?

Eisai Innovation invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Seed and Pre-Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eisai Innovation last invest?

The most recent investment recorded for Eisai Innovation closed in Apr 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co